The Ministry of Health of the Government of Canarias has resumed the administration of the Astrazéneca vaccine, which has now been extended from the age of 55 to 65. In fact, priority will be given to people between 60 and 65 years old.
This was reported by the regional Executive, which adds that this restart is carried out "with the guarantees of safety and efficacy demonstrated according to scientific evidence, as pointed out by the Committee for Risk Assessment in Pharmacovigilance (PRAC) of the European Medicines Agency (EMA), the Public Health Commission and recent observational studies in the United Kingdom".
In addition to continuing to vaccinate large dependent households and those over 80 years of age with a second dose, vaccination resumed this Wednesday with Astrazéneca, for the 144,000 people between 60 and 65 years of age in the Canary Islands.
Similarly, groups 3 and 6 continue, which include health and social health workers not previously vaccinated, workers in penitentiary institutions or other essential workers for society such as teachers and special education, infant, primary and secondary school staff or those belonging to the Security Forces, Emergency Services and Armed Forces.
Almost 245,000 doses administered
As of Tuesday, a total of 244,932 doses of vaccines against Covid-19 had been administered in the Canary Islands and immunization has already been achieved in 87,467 people who have already received both doses in the Canary Islands, representing 6.5 percent of the target population.
By groups, the complete vaccination coverages with two doses correspond to groups 1 and 2; while group 3 is at 99.3 percent with one dose and 19.2 with two doses; group 4, at 87.9 percent with one dose and 52 percent with two; group 5, at 36.3 percent with one dose and 11.5 with two doses and group 6 at 26.3 percent with one dose.
The Canarian Government recalls that "after vaccination, mild local and/or systemic reactions may appear, such as local pain, mild fever, chills, myalgia, headache and malaise. In this regard, they explain that "in clinical trials these reactions were more common after the first dose and usually resolve spontaneously in 12-24 hours".
